| Filed On | Filing |
|---|---|
| 14 Oct 2026 |
8-K: Other Events
On October 14, 2026, the Board of Directors of Neuraxis, Inc. (the “Company”) authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) for... |
| 19 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
As previously disclosed, on June 10, 2026, the stockholders of Neuraxis, Inc. (the “Company”) approved the cancellation of 1,319,394 outstanding stock options previously granted under the Innovative Health Solutions, Inc. 2017 Stock Comp... |
| 10 Jul 2026 |
8-K: Other Events
On July 9, 2026, the Board of Directors of Neuraxis, Inc. (the “Company”) authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) for the... |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The purpose of this Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (the “Plan”) is to benefit the stockholders of Neuraxis, Inc., a Delaware corporation (the “Company”), by assisting the Company to attract, retain and provide ... |
| 22 Apr 2026 |
8-K: Other Events
We have acted as counsel to Neuraxis, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended... |
| 21 Apr 2026 |
8-K: Results of Operations and Financial Condition
On April 21, 2026, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. The Company expects its... |
| 24 Oct 2025 |
8-K: Other Events
We have acted as counsel to Neuraxis, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended... |
| 23 Oct 2025 |
8-K: Results of Operations and Financial Condition
On October 23, 2025, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $4.4 million as of September 30, 2025. On a preliminary ... |
| 02 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
Neuraxis, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Craig-Hallum Capital Group LLC (the “Manager”) as follows: |
| 03 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
(a) The Plan provides a means by which Eligible Employees of the Company may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Emp... |
| 04 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 29, 2025, Neuraxis, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”) at 11611 N. Meridian Street, Suite 330, Carmel, Indiana 46032. |
| 28 May 2025 |
8-K: Regulation FD Disclosure
On May 23, 2025, Neuraxis, Inc. (the “Company”) posted an investor presentation (the “Investor Presentation”) to its website located at https://ir.neuraxis.com/. The Investor Presentation provides an overview of the Company’s strategy, p... |
| 22 May 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of May 20, 2025, between Neuraxis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successor... |
| 21 May 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
This Settlement Agreement and Mutual Release (“Agreement”) is entered into by and among (1) Ritu Bhambhani, M.D. (“Dr. Bhambhani”), (2) Sudhir Rao, M.D. (“Dr. Rao”), (3) Ritu Bhambhani, LLC d/b/a Complete Care of Maryland (“Bhambhani LLC... |
| 08 Jan 2025 |
8-K: Results of Operations and Financial Condition
Carmel, Ind., (January 8, 2025) (GLOBE NEWSWIRE) – NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions... |
| 25 Nov 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
As previously reported, on November 9, 2024, Neuraxis, Inc. (the “Company”) entered into securities purchase agreements (the “SPAs”) with three related investors (the “Investors”) for the issuance and purchase of a total of 2,100,840 sha... |
| 21 Nov 2024 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
(Pursuant to Section 151 of the Delaware General Corporate Law) |
| 15 Nov 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”), dated as of November 9, 2024, is entered into by and between Neuraxis, Inc., a Delaware corporation (the “Company”) and the investors named on the signatory pages hereto (each an “In... |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
Carmel, Ind., November 12, 2024 (GLOBE NEWSWIRE)—NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in child... |
| 18 Oct 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”), dated as of October [_], 2024, is entered into by and between Neuraxis, Inc., a Delaware corporation (the “Company”) and the investors named on the signatory pages hereto (each an “I... |
Loading...